FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer's Disease Study, Streamlining Development Pathway

Stock Information for Annovis Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Annovis Bio Inc.

Annovis to Attend the AAIC 2025 with Four Poster Presentations
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance
Annovis to Host Webinar and Live Q&A on June 24, 2025
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results
Annovis Bio Appoints Hui Liu as Director of Biostatistics
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
Annovis to Attend AD/PD(TM) 2025 with Extensive Scientific Program
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.